Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

19/06/2014 ALBA synchrotron welcomes the one thousandth researcher 12/06/2014 € 1.365 billion of foreign investment in the Catalan industry in 2013 03/06/2014 Barcelona Synchroton Park booth at the BioKorea 2014 exhibition in Seoul 27/05/2014 The new Barcelona Synchrotron Park bus shuttle completes its first six months 20/05/2014 SENER opens in the Barcelona Synchrotron Park its new corporate headquarters in Catalonia 15/05/2014 MATGAS, Air Products' leading R&D centre worldwide
40 41 42 43 44 45 46 47 48 49